These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16538619)

  • 1. Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial.
    Sato Y; Iwamoto J; Kanoko T; Satoh K
    Mov Disord; 2006 Jul; 21(7):924-9. PubMed ID: 16538619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
    Sato Y; Honda Y; Iwamoto J
    Neurology; 2007 Mar; 68(12):911-5. PubMed ID: 17372126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial.
    Sato Y; Iwamoto J; Honda Y
    J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1390-3. PubMed ID: 21825080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
    Ringe JD; Farahmand P; Schacht E; Rozehnal A
    Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
    J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
    Hochberg MC; Ross PD; Black D; Cummings SR; Genant HK; Nevitt MC; Barrett-Connor E; Musliner T; Thompson D
    Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
    Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
    JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
    Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
    J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
    Garnero P; Hausherr E; Chapuy MC; Marcelli C; Grandjean H; Muller C; Cormier C; Bréart G; Meunier PJ; Delmas PD
    J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
    Hochberg MC; Thompson DE; Black DM; Quandt SA; Cauley J; Geusens P; Ross PD; Baran D;
    J Bone Miner Res; 2005 Jun; 20(6):971-6. PubMed ID: 15883637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of alendronate in elderly patients after low trauma hip fracture repair.
    Cecilia D; Jódar E; Fernández C; Resines C; Hawkins F
    Osteoporos Int; 2009 Jun; 20(6):903-10. PubMed ID: 18956132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial.
    Sato Y; Iwamoto J; Kanoko T; Satoh K
    Cerebrovasc Dis; 2005; 20(3):187-92. PubMed ID: 16088114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
    Black DM; Cummings SR; Karpf DB; Cauley JA; Thompson DE; Nevitt MC; Bauer DC; Genant HK; Haskell WL; Marcus R; Ott SM; Torner JC; Quandt SA; Reiss TF; Ensrud KE
    Lancet; 1996 Dec; 348(9041):1535-41. PubMed ID: 8950879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immobilization and hip fracture].
    Sato Y
    Clin Calcium; 2006 Dec; 16(12):1991-98. PubMed ID: 17142929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.